Sawyer & Company’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.71M | Sell |
10,757
-65
| -0.6% | -$14K | 0.91% | 39 |
|
|
2026
Q1 | $2.35M | Sell |
10,822
-635
| -6% | -$141K | 0.91% | 42 |
|
|
2025
Q4 | $2.62M | Sell |
11,457
-1,426
| -11% | -$325K | 0.93% | 37 |
|
|
2025
Q3 | $2.39M | Buy |
12,883
+2,126
| +20% | +$433K | 0.9% | 41 |
|
|
2025
Q2 | $2.71M | Sell |
10,757
-2,138
| -17% | -$397K | 0.91% | 39 |
|
|
2025
Q1 | $2.7M | Sell |
12,895
-365
| -3% | -$71K | 1.09% | 39 |
|
|
2024
Q4 | $2.36M | Sell |
13,260
-3,161
| -19% | -$581K | 0.87% | 42 |
|
|
2024
Q3 | $3.24M | Sell |
16,421
-592
| -3% | -$110K | 1.2% | 33 |
|
|
2024
Q2 | $2.92M | Sell |
17,013
-120
| -0.7% | -$19.9K | 1.16% | 35 |
|
|
2024
Q1 | $3.12M | Sell |
17,133
-320
| -2% | -$55.1K | 1.25% | 32 |
|
|
2023
Q4 | $2.71M | Sell |
17,453
-931
| -5% | -$136K | 1.19% | 36 |
|
|
2023
Q3 | $2.74M | Buy |
18,384
+100
| +0.5% | +$14.7K | 1.28% | 29 |
|
|
2023
Q2 | $2.46M | Hold |
18,284
| – | – | 1.13% | 35 |
|
|
2023
Q1 | $2.95M | Sell |
18,284
-992
| -5% | -$152K | 1.59% | 20 |
|
|
2022
Q4 | $3.12M | Sell |
19,276
-40
| -0.2% | -$6.13K | 1.53% | 20 |
|
|
2022
Q3 | $2.59M | Sell |
19,316
-250
| -1% | -$35.9K | 1.41% | 23 |
|
|
2022
Q2 | $3M | Sell |
19,566
-1,302
| -6% | -$199K | 1.52% | 22 |
|
|
2022
Q1 | $3.38M | Sell |
20,868
-35
| -0.2% | -$5.08K | 1.52% | 20 |
|
|
2021
Q4 | $2.83M | Sell |
20,903
-106
| -0.5% | -$12.5K | 1.22% | 27 |
|
|
2021
Q3 | $2.27M | Buy |
21,009
+320
| +2% | +$36.6K | 1.07% | 38 |
|
|
2021
Q2 | $2.33M | Buy |
20,689
+315
| +2% | +$35.5K | 1.09% | 35 |
|
|
2021
Q1 | $2.21M | Hold |
20,374
| – | – | 1.1% | 33 |
|
|
2020
Q4 | $2.18M | Sell |
20,374
-85
| -0.4% | -$8.17K | 1.11% | 31 |
|
|
2020
Q3 | $1.79M | Sell |
20,459
-156
| -0.8% | -$14.7K | 1.07% | 32 |
|
|
2020
Q2 | $2.02M | Sell |
20,615
-90
| -0.4% | -$7.92K | 1.25% | 26 |
|
|
2020
Q1 | $1.58M | Sell |
20,705
-370
| -2% | -$31.5K | 1.26% | 25 |
|
|
2019
Q4 | $1.87M | Buy |
21,075
+115
| +0.5% | +$9.55K | 1.2% | 27 |
|
|
2019
Q3 | $1.59M | Sell |
20,960
-840
| -4% | -$57.6K | 1.13% | 31 |
|
|
2019
Q2 | $1.58M | Sell |
21,800
-575
| -3% | -$45.2K | 1.06% | 31 |
|
|
2019
Q1 | $1.8M | Buy |
22,375
+375
| +2% | +$30.7K | 1.18% | 29 |
|
|
2018
Q4 | $2.03M | Sell |
22,000
-815
| -4% | -$71.7K | 1.49% | 22 |
|
|
2018
Q3 | $2.16M | Buy |
22,815
+1,805
| +9% | +$171K | 1.32% | 24 |
|
|
2018
Q2 | $1.95M | Buy |
21,010
+500
| +2% | +$48.8K | 1.27% | 23 |
|
|
2018
Q1 | $1.94M | Hold |
20,510
| – | – | 1.31% | 21 |
|
|
2017
Q4 | $1.98M | Buy |
+20,510
| New | +$1.93M | 1.3% | 24 |
|
Other funds holding ABBV
ECSS
ATO
Sawyer & Company's ABBV Position: Q2 2026 in Review
Sawyer & Company reduced its AbbVie (ABBV) stake by 0.6% in Q2 2026, selling an estimated $14K and leaving 10,757 shares worth $2.71M. The position accounts for 0.91% of the portfolio, ranked #39.
Sawyer & Company first reported a position in ABBV in Q4 2017 and has held it in 35 quarters since. The position peaked at $3.38M in Q1 2022. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Sawyer & Company held 10,757 shares of AbbVie worth $2.71M as of Q2 2026.
- Sawyer & Company sold 65 AbbVie shares in Q2 2026, an estimated $14K.
- AbbVie made up 0.91% of Sawyer & Company's portfolio in Q2 2026, its #39 holding.
- Sawyer & Company first reported a position in AbbVie in Q4 2017 and has held it in 35 quarters since.
- Sawyer & Company's AbbVie position peaked at $3.38M in Q1 2022.
- 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Sawyer & Company's 13F filing for Q2 2026, filed 23 Jul 2026.